Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Advanced Triple-Negative Breast Cancer
DRUG: Vinorelbine|DRUG: Apatinib
PFS, Progression Free Survival, 6 weeks
OS, Overall Survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months|ORR, Objective Response Rate, 6 weeks|Safety: Number of Participants with Adverse Events, Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 6 weeks
A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Second-Line or Third-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer (NAN trail)